Vibalogics with an investment of US$ 150 million plans to enter the US region to expand Virotherapy Facility. The new facility will be located in Boston.
The project features initial Phase I of the facility constructed with an area of 110,000 sq. Ft.
The new state-of-the-art facility consists of advanced technology which significantly enhances the size of the capacity which includes 2000L scale bioreactors and additional fill-finish capabilities.
The facility designed with new technology and virotherapy services will enhance the production of drug developers with most innovative products. Moreover, with the construction of a new state-of-the-art facility the consumer products can be made easily available from the early phase manufacturing facility in Germany to the US.
It is expected that the new clinical and commercial facility will create 100 jobs initially and reach out to 250 employees in the coming years.
The new project is expected to begin its operations by the second half of 2021.
|New Manufacturing Facility